SAVER
Statins for Venous Event Reduction in Patients with Venous Thromboembolism
Registration:
(Clinicaltrials.gov) NCT04319627
Sponsors:
Ottawa Hospital Research Institute
Status:
- Pilot trial recruitment completed in Canada and Norway
- Secured Funding to Begin Full Trial
Design
A multicentre, prospective, randomized, double-blinded, placebo controlled trial of rosuvastatin (20 mg) for prevention of recurrent VTE (primary outcome), PTS and arterial vascular events (secondary outcomes).
Participating Sites
Lead Network:
CanVECTOR
Countries:
Canada,Subscribe